Vivoryon Therapeutics N.V. (LON:0R3M)

London flag London · Delayed Price · Currency is GBP · Price in EUR
1.414
-0.036 (-2.48%)
Feb 12, 2026, 12:21 PM GMT
Market Cap37.34M -11.8%
Revenue (ttm)n/a
Net Income-10.70M
EPS-0.41
Shares Outn/a
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume22
Average Volume187
Open1.450
Previous Close1.450
Day's Range1.414 - 1.450
52-Week Range1.400 - 2.255
Beta1.50
RSI40.31
Earnings DateApr 24, 2026

About Vivoryon Therapeutics

Vivoryon Therapeutics N.V. operates as a clinical stage biopharmaceutical company that focuses on research, development, and commercialize small molecule-based medicines. Its pipeline products target toxic pyroglutamate-Abeta (pGlu-Abeta), which inhibits the production of pGlu-Abeta. The company’s lead product candidate is PQ912, a nanomolar QPCT inhibitor that has completed Phase IIb clinical trials for use in the treatment of Alzheimer’s disease. In addition, the company is developing a monoclonal antibody PBD-C06 is for N3pE-Abeta. Vivoryon ... [Read more]

Industry Medical - Pharmaceuticals
Sector Healthcare
Founded 1997
Employees 14
Stock Exchange London Stock Exchange
Ticker Symbol 0R3M
Full Company Profile

Financial Performance

Financial numbers in EUR Financial Statements